Download PDF
Semin Thromb Hemost 2002; 28(s3): 033-040
DOI: 10.1055/s-2002-34073
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Mapping Out the Future in Venous Thromboembolism and Acute Coronary Syndromes

John A. Heit
  • Division of Cardiovascular Diseases, Section of Vascular Diseases, and the Division of Hematology, Section of Hematology Research, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota
Further Information

Publication History

Publication Date:
16 September 2002 (online)

    Permissions and Reprints

ABSTRACT

Identification of risk factors for incident venous thromboembolism and predictors of recurrent venous thromboembolism and appropriate antithrombotic prophylaxis and therapy are vital to improve survival after pulmonary embolism and prevent complications such as venous stasis syndrome after deep-vein thrombosis. Risk stratification is increasingly important; future prophylaxis and treatment strategies should be targeted to the patients who will derive the greatest benefit. For established antithrombotic agents, the most appropriate dose, dosing schedule, and duration of prophylaxis and therapy are being refined. In addition, new antithrombotic agents such as the oral direct thrombin inhibitors are being identified and developed. The management of acute arterial thrombosis (for example, acute coronary syndromes) is an important and relatively new indication for antithrombotic agents such as the low-molecular-weight heparins and the platelet glycoprotein IIb/IIIa antagonists.

KEYWORDS

Venous thromboembolism - acute coronary syndromes - thromboprophylaxis - antithrombotic agents - low-molecular-weight heparin

REFERENCES

  • 1 Heit J A, Silverstein M D, Mohr D N. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study.  Arch Intern Med . 1999;  159 445-453
    CrossrefPubMedGoogle Scholar
  • 2 Prandoni P, Villalta S, Bagatella P. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients.  Haematologica . 1997;  82 423-428
    PubMedGoogle Scholar
  • 3 Heit J A, Silverstein M D, Mohr D N. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.  Arch Intern Med . 2000;  160 809-815
    CrossrefPubMedGoogle Scholar
  • 4 Heit J A, O'Fallon W M, Petterson T M. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study.  Arch Intern Med . 2002;  162 1245-1246
    CrossrefPubMedGoogle Scholar
  • 5 Turpie A G, Gallus A S, Hoek J A, Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.  N Engl J Med . 2001;  344 619-625
    CrossrefPubMedGoogle Scholar
  • 6 Eriksson B I, Bauer K A, Lassen M R, Turpie A GG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture study.  N Engl J Med . 2001;  345 1298-1304
    CrossrefPubMedGoogle Scholar
  • 7 Bauer K A, Eriksson B I, Lassen M R, Turpie A GG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.  N Engl J Med . 2001;  345 1305-1310
    CrossrefPubMedGoogle Scholar
  • 8 Hull R D, Pineo G F, Francis C. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery versus warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators.  Arch Intern Med . 2000;  160 2199-2207
    CrossrefPubMedGoogle Scholar
  • 9 Eriksson B I, Ekman S, Kalebo P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.  Lancet . 1996;  347 635-639
    CrossrefPubMedGoogle Scholar
  • 10 Heit J A. Low-molecular-weight heparin: the optimal duration of prophylaxis against postoperative venous thromboembolism after total hip or knee replacement.  Thromb Res . 2001;  101 V163-V173
    CrossrefPubMedGoogle Scholar
  • 11 Weitz J I, Hirsh J. New anticoagulant drugs.  Chest . 2001;  119 95S-107S
    CrossrefPubMedGoogle Scholar
  • 12 Lee A, Agnelli G, Buller H. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement.  Circulation . 2001;  104 74-78
    PubMedGoogle Scholar
  • 13 Heit J A, Colwell C W, Francis C W. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. A phase 2 dose-finding study.  Arch Intern Med . 2001;  161 2215-2221
    CrossrefPubMedGoogle Scholar
  • 14 Stewart G J. Neutrophils and deep venous thrombosis.  Haemostasis . 1993;  23(Suppl 1) 127-140
    PubMedGoogle Scholar
  • 15 Wakefield T W, Strieter R M, Schaub R. Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulation therapy.  J Vasc Surg . 2000;  31 309-324
    PubMedGoogle Scholar
  • 16 White R, Zhou H, Kim J, Romano P S. A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism.  Arch Intern Med . 2000;  160 2033-2041
    CrossrefPubMedGoogle Scholar
  • 17 Hyers T M, Agnelli G, Hull R D. Antithrombotic therapy for venous thromboembolic disease.  Chest . 2001;  119 176S-193S
    CrossrefPubMedGoogle Scholar
  • 18 Hutten B A, Prins M H, Gent M. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.  J Clin Oncol . 2000;  18 3078-3083
    PubMedGoogle Scholar
  • 19 Cairns J A, Théroux P, Lewis Jr D H, Ezekowitz M, Meade T W. Antithrombotic agents in coronary artery disease.  Chest . 2001;  119 228S-252S
    CrossrefPubMedGoogle Scholar
  • 20 Cohen M, Demers C, Gurfinkel E P. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.  N Engl J Med . 1997;  337 447-452
    CrossrefPubMedGoogle Scholar
  • 21 Antman E M, McCabe C H, Gurfinkel E P. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.  Circulation . 1999;  100 1593-1601
    PubMedGoogle Scholar
  • 22 Fox K AA, Bosanquet N. Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease.  Br J Cardiol . 1998;  5 92-105
    PubMedGoogle Scholar
  • 23 Balen R M, Marra C A, Zed P J, Cohen M, Frighetto L. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective.  Pharmacoeconomics . 1999;  16 533-542
    PubMedGoogle Scholar
  • 24 Mark D B, Cowper P A, Berkowitz S D. Economic assessment of low-molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial.  Circulation . 1998;  97 1702-1707
    PubMedGoogle Scholar
  • 25 Goodman S G, Cohen M, Bigonzi F. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.  J Am Coll Cardiol . 2000;  36 693-698
    PubMedGoogle Scholar
  • 26 Cannon C P, Weintraub W S, Demopoulos L A. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.  N Engl J Med . 2001;  344 1879-1887
    CrossrefPubMedGoogle Scholar
  • 27 Wallentin L, Lagerqvist B, Husted S. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.  Lancet . 2000;  356 9-16
    CrossrefPubMedGoogle Scholar
  • 28 Kereiakes D J, Grines C, Fry E, for the NICE 1 and 4 Investigators et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.  J Invas Cardiol . 2001;  13 272-278
    PubMedGoogle Scholar
  • 29 Ferguson J J, Antman E M, Bates E R, for the NICE 3 Investigators et al. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: final results of the NICE 3 Study.  J Am Coll Cardiol. 2001;  37(Suppl A) 1253-1297 (Abst)
    PubMedGoogle Scholar
      >